| Literature DB >> 31437076 |
Shunsuke Nakamura1, Mitsuro Kanda1, Yasuhiro Kodera1.
Abstract
Introduction: Gastric cancer is one of the most common causes of cancer-related mortality worldwide. To improve clinical outcomes, it is critical to develop appropriate approaches to diagnosis and treatment. Biomarkers have numerous potential clinical applications, including screening, assessing risk, determining prognosis, monitoring recurrence, and predicting response to treatment. Furthermore, biomarkers may contribute to the development of effective therapies. Areas covered: Here we review recent progress in exploiting GC-specific biomarkers such as protein-coding genes, microRNAs, long noncoding RNAs, and methylated gene promoters. Expert opinion: The development of biomarkers for diagnosing and monitoring gastric cancer and for individualizing therapeutic targets shows great promise for improving gastric cancer management.Entities:
Keywords: Biomarker; DNA methylation; gastric cancer; long noncoding RNA; microRNA
Mesh:
Substances:
Year: 2019 PMID: 31437076 DOI: 10.1080/14737140.2019.1659136
Source DB: PubMed Journal: Expert Rev Anticancer Ther ISSN: 1473-7140 Impact factor: 4.512